Background: Due to their chemical nature as fluorinated hydrocarbon compounds, volatile anesthetics are highly potent greenhouse gases, with desflurane having by far the largest CO2-equivalent (CO2e) footprint. In everyday clinical practice, the CO2e footprint can easily be reduced through the increased use of propofol or sevoflurane as well as low- and minimal-flow techniques or through the more frequent use of regional anesthesia techniques. We wanted to assess to what extent educational measures on sustainability aspects of the use of volatile anesthetics had an impact on daily practice in anesthesiology departments and to what extent this influenced the hospital's CO2e emissions.
Methods: We conducted an observational data analysis of the consumption of anesthetics (sevoflurane, desflurane, isoflurane, and propofol) at all 3 clinical Charité campuses in the period from 2015 to 2023. The CO2e emissions were calculated for sevoflurane, desflurane, and isoflurane. External and internal (top-down or bottom-up) educational measures focusing on sustainability in anesthesia took place from September 2018 on. Shifts in CO2e emissions related to the educational measures are shown in a run chart. The number of surgeries, surgery duration, and purchasing costs were included in the analysis.
Results: CO2e emissions of volatile anesthetics were reduced by 90.3% from the baseline epoch (years 2015-2017) before educational interventions took place to 2023: CO2e 1470 tons (mean 2015-2017), to 191 tons (2022) to 142 tons (2023). This change was brought about by the phasing out of desflurane and the use of propofol or sevoflurane and regional anesthesia where appropriate. The fastest and most sustainable changes were seen after internal top-down measures. The total cost of anesthetics also fell over the period under review (from €541,102/$594,238 in 2015 to €281,646/$309,303 in 2023).
Conclusions: Educational measures for anesthesiologists about the climate-damaging effects of volatile anesthetics-especially desflurane-can significantly reduce CO2e emissions in anesthesia clinics. On the positive side, these measures have also reduced the annual costs for anesthetics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/ANE.0000000000007375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Using gut microbiota and non-targeted metabolomics techniques to study the effect of xylitol on alleviating DSS-induced inflammatory bowel disease in mice.
BMC Immunol
March 2025
Department of Laboratory Medicine, Taizhou Second People's Hospital, Taizhou, 225309, China.
Background: Inflammatory bowel disease (IBD) has become a global healthcare issue, with its incidence continuing to rise, but currently there is no complete cure. Xylitol is a widely used sweetener in various foods and beverages, but there is limited research on the effects of xylitol on IBD symptoms.
Aim: Study on the effect of oral xylitol in improving intestinal inflammation and damage in IBD mice, further explore the mechanism of xylitol in alleviating IBD symptoms using intestinal microbiota and non-targeted metabolomics techniques.
Effects of Perioperative Exposure on the Microbiome and Outcomes From an Immune Challenge in C57Bl/6 Adult Mice.
Anesth Analg
March 2025
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Background: Previous work suggests that the gut microbiome can be disrupted by antibiotics, anesthetics, opiates, supplemental oxygen, or nutritional deprivation-all of which are common and potentially modifiable perioperative interventions that nearly all patients are exposed to in the setting of surgery. Gut microbial dysbiosis has been postulated to be a risk factor for poor surgical outcomes, but how perioperative care-independent of the surgical intervention-impacts the gut microbiome, and the potential consequences of this impact have not been directly investigated.
Methods: We developed a perioperative exposure model (PEM) in C57Bl/6 mice to emulate the most common elements of perioperative medicine other than surgery, which included 12 hours of nutritional deprivation, 4 hours of volatile general anesthetic, 7 hours of supplemental oxygen, surgical antibiotics (cefazolin), and opioid pain medication (buprenorphine).
Choice of Anesthetic for Laparoscopic Bariatric Surgery Can Reduce the Use of Rescue Antiemetics in Postanesthesia Recovery Room: A Retrospective Observational Study.
Surg Laparosc Endosc Percutan Tech
March 2025
Department of Anesthesiology and Perioperative Medicine.
Objective: Postoperative nausea and vomiting (PONV) is a frequent adverse event after bariatric surgery and is associated with patient dissatisfaction and increased health care burden. Aggressive multimodal antiemetic prophylaxis and the use of propofol infusion during anesthesia are associated with the reduction of PONV. In this study, we examined the use of rescue antiemetics following bariatric surgery performed with 3 different anesthetic strategies designed to reduce PONV: (1) primary volatile (VOL) anesthetic and propofol (PROP) infusion (VOL+PROP), (2) volatile anesthetic with propofol and dexmedetomidine (DEX) infusions (VOL+PROP+DEX), or (3) opioid-sparing total intravenous anesthesia (PROP+DEX).
View Article and Find Full Text PDFEffectiveness and tolerability of methylthioninium chloride (methylene blue) for the treatment of methemoglobinemia: twenty-four years of experience at a single poison center.
Clin Toxicol (Phila)
March 2025
Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Introduction: Despite the widely accepted use of methylthioninium chloride (methylene blue) to treat methemoglobinemia, data regarding clinical outcomes are sparse. We sought to better elucidate the efficacy and tolerability of methylthioninium chloride.
Methods: We identified all cases reported to the New York City Poison Center from 2000 to 2024 in which methylthioninium chloride was administered for methemoglobinemia.
Anesthetic Agents as Therapeutic Tools in Breast Cancer: Insights into Cancer Progression and Recurrence.
Clin Breast Cancer
February 2025
Department of Intensive Care Unit, The Third People's Hospital of Chengdu, Chengdu, 610031, China. Electronic address:
Breast cancer (BC) remains one of the leading causes of cancer-related mortality worldwide, necessitating continuous advancements in therapeutic strategies. While anesthetic agents are traditionally used for managing pain and sedation during BC surgeries, emerging evidence suggests their potential influence on cancer progression and recurrence. This comprehensive review examines the role of various anesthetic agents as therapeutic tools in BC, exploring the molecular mechanisms underlying their interaction with tumor biology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!